| A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A | Würzburg, Münster | Phase I | rekrutiert |
| A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa | Altenburg, Bochum, Göppingen | — | rekrutiert |
| A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy | Würzburg | Phase I / Phase II | rekrutiert |
| A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Mar | Würzburg, Münster, Jena | Phase III | rekrutiert |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or | Heidelberg, München, Würzburg | Phase I / Phase II | rekrutiert |
| An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly | Aachen, Leipzig, Magdeburg | — | rekrutiert |
| Analysis of TPE Treatments With multiFiltratePRO | Aschaffenburg, Würzburg, Berlin | — | rekrutiert |
| Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study | Passau, Würzburg, Bremen | — | rekrutiert |
| BIO|MASTER.CorSky Family Post-market Study for the CorSky Family of ICDs | Würzburg, Gera | — | rekrutiert |
| Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL) | Baden-Baden, Heidelberg, Mannheim | — | rekrutiert |
| Clinical Performance of the New Plasma Filter PX2 in TPE Treatments | Aschaffenburg, München, Braunschweig | ohne Phasenangabe | rekrutiert |
| Corheart 6 LVAS Study | Bad Oeynhausen, Berlin, Bremen | ohne Phasenangabe | rekrutiert |
| Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Pa | Berlin, Bielefeld, Hamburg | Phase II / Phase III | rekrutiert |
| GISAR German Interdisciplinary Sarcoma Registry | Tübingen, Erlangen, Bad Saarow | — | rekrutiert |
| GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, T | Frankfurt am Main, Aachen, Altenburg | — | rekrutiert |
| Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITIO | Heidelberg, Tübingen, Augsburg | Phase II | rekrutiert |
| Giant Cell Arteritis - Ways to Precision Medicine | Würzburg | — | rekrutiert |
| ITP Registry and Accompanying Biospecimen Collection | Aachen, Altenburg, Aschaffenburg | — | rekrutiert |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Berlin, Ulm, Würzburg | Phase I | rekrutiert |
| LEOPARD Training and Validation Data Collection Study | Aachen, Berlin, Hannover | — | rekrutiert |
| Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I | München, Würzburg | Phase III | rekrutiert |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma | Tübingen, Ulm, Erlangen | Phase III | rekrutiert |
| Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab | Heidelberg, Mannheim, Tübingen | Phase II | rekrutiert |
| Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Mali | Ulm, München, Würzburg | Phase I | rekrutiert |
| Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region | Augsburg, Würzburg, Berlin | — | rekrutiert |
| Praegnant Breast Cancer: Early/Advanced/Metastatic | Böblingen, Freiburg im Breisgau, Heidelberg | — | rekrutiert |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blin | Aachen, Aschaffenburg, Augsburg | Phase II | rekrutiert |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Berlin, Köln, Cottbus - Chóśebuz | Phase III | rekrutiert |
| Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | Berlin, Köln, Düsseldorf | — | rekrutiert |
| Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in | Mannheim, Fürth, Würzburg | ohne Phasenangabe | rekrutiert |
| Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI) | Bremerhaven, Erlangen, Lübeck | ohne Phasenangabe | rekrutiert |
| The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in I | Aachen, Amberg, Berlin | Phase III | rekrutiert |
| Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephali | München, Würzburg, Jena | Phase II | rekrutiert |